MYM Nutraceuticals Inc., (CSE:MYM,CSE: MYM.CN,OTC:MYMMF) (the “Company” or “MYM”) is pleased to announce that it and its subsidiary, Sublime Culture Inc., have entered into a consulting agreement with Sasha Przytyk, who will act as Master Breeder at the Sublime facility in Laval, Québec.
As Master Breeder, Mr. Przytyk will be responsible for developing a comprehensive Cannabis seed breeding and production program for Sublime Culture and MYM. His initial focus will be to search out and select source seed varieties from breeders and reputable international seed houses. In parallel, Sasha will design and conduct an ongoing research program, to evaluate and analyze seed strains under varying conditions. In the long term, Sasha promises to create improved, proprietary varieties through selection and hybridization, to supply the Canadian and international cannabis seed market.
Sasha has extensive experience in the medicinal cannabis and horticultural sector. He is a designated cannabis grower, licensed through Health Canada’s MMAR and AMCPR programs since 2009. Sasha was the first private recipient of a Health Canada Industrial Hemp Research license in Québec. He is currently the owner of a cannabis seed brand-management company, Shazam Farms International Inc.
Sasha has extensive experience as a guest speaker and delegate at international cannabis conferences and symposiums. He is also an accomplished publisher in the field, writing numerous articles on hemp and its cultivation.
Sasha established ‘The Joint Doctor’ and ‘High-Bred Seeds’ as world-renowned seed brands. Through the revolutionary strain ‘Lowryder,’ he introduced the concept of autoflowering cannabis. Lowryder is recognized worldwide as the first 100% autoflowering variety and The Joint Doctor has been dubbed the ‘Father of Autoflowering.’ Widely adopted by seed companies today, autoflowering strains now represent approximately 40% of the European seed market.
“We are thrilled to welcome Sasha to the MYM team as Master Breeder. His experience in the hemp, cannabis, and horticultural industry is unparalleled,” said Rob Gietl, MYM’s CEO. “Sasha’s innovation in seed technology will prove to be a valuable asset to the shareholders of MYM as growing cannabis becomes increasingly accepted and adopted around the world.”
Pursuant to the five-year consulting agreement, which is with Mr. Przytyk’s company, Shazam Farms, Sasha will receive a signing bonus of $25,000, paid in 7,062 MYM common shares at a deemed price per share of $3.54.
About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in Québec that when completed will have over 1.5 million square feet of production space. MYM is also a partner in a 1.2 million square-foot production project (the Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC: MYMMF) (FRA: 0MY) (DEU: 0MY) (MUN: 0MY) (STU: 0MY).
On Behalf of the Board
Rob Gietl, CEO
MYM Nutraceuticals Inc.
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States.The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the ‘U.S. Securities Act’), or any state securities law and may not be offered or sold in the ‘United States’, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
Click here to connect with MYM Nutraceuticals Inc. (CSE:MYM,CSE: MYM.CN,OTC:MYMMF) for an Investor Presentation
Both locations expand access to the state’s widest-ranging inventory of medical cannabis products for Central Florida patients
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two brand-new Central Florida dispensaries. The new Clearwater and Tampa locations mark the Company’s 81 st and 82 nd nationwide, respectively, widening patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Philip Young, CEO and Director of Lobe, stated, “We are honored to welcome Bart to our Advisory Board. His first-hand experience on and off the field are tremendously valuable as we continue our research involving mild traumatic brain injuries and PTSD. These issues are prevalent in contact sports and we believe that athletes will play a prominent role in the continued acceptance of psychedelic medicines as legitimate treatment. We look forward to working with Bart as we seek to forge long-term strategic relationships.”
HempFusion Wellness Submits Novel Foods Dossier to the United Kingdom’s Regulatory Food Safety Agency
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has submitted its dossier to the United Kingdom’s Regulatory Food Safety Agency (the “FSA”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005322/en/